Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

ZVRA US Equity

Zevra Therapeutics, Inc.Health Care · Pharmaceutical Preparations · CIK 1434647 · FY ends Dec 31
$12.13
+0.56 (+4.84%)
USD · as of 2026-08-19 · marketstack
3 registered studies · 0 active

Studies where ZVRA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

3 interventional · 3 with posted results

Held by 10 tracked-famous managers (D. E. Shaw & Co., Inc., Qube Research & Technologies Ltd, SUSQUEHANNA INTERNATIONAL GROUP, LLP, AQR CAPITAL MANAGEMENT LLC, MILLENNIUM MANAGEMENT LLC, +5 more) · FINRA short interest 4.4 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: none disclosed

StudyPhaseStatusInterventionsConditionsEnrollmentPrimary completionUpdated
Study of SDX in Patients With Idiopathic Hypersomnia (IH)NCT05668754results2026-06-30Change From Baseline in Epworth Sleepiness Scale (ESS) ScoreRandomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis PlanPhase 2CompletedDrug: Serdexmethylphenidate · Other: PlaceboIdiopathic Hypersomnia662024-02-28actual2026-06-30
KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHDNCT03460652results2021-07-19Subjects With Treatment-Emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol · Statistical Analysis PlanPhase 3CompletedDrug: KP415 oral capsuleADHD2822019-06-20actual2021-07-19
KP415 Classroom Study in Children (6-12 Years of Age) With ADHDNCT03292952results2021-06-30Change From Baseline in Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Combined ScoresRandomized · Quadruple-masked · TreatmentStudy Protocol · Statistical Analysis Plan: Statistical Analysis Plan · Statistical Analysis Plan: Statistical Analysis Plan AddendumPhase 3CompletedDrug: KP415 oral capsule, Placebo oral capsuleADHD1552018-05-16actual2021-06-30

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19